Quest PharmaTech Inc. (Quest) is a Canada-based biotechnology company. Quest is engaged in the development of the monoclonal antibody, Oregovomab (MAb B43.13), for the treatment of ovarian cancer. Quest's pipeline of product candidates consists of four monoclonal antibodies targeting certain tumor antigens that are presented in a range of cancers, including such cancers as breast, lung, pancreas, stomach and prostate. Quest has antibodies against MUC1, PSA, CA19.9 and TAG72. The Company's products, SL017, a topical formulation indicated for dermatology applications, and SL052, an injectable formulation, are developed using the SonoLight Technology. Quest has a supply and distribution agreement with Smart Cell Tec for the marketing and distribution rights for the anti-wrinkle skin care product, Bellus Skin. Quest is engaged in conducting two Phase II trials for its Oregovomab product for advanced ovarian cancer and for CA125 associated partially resectable pancreatic cancer.